Genitourinary syndrome of menopause: diagnosis and principles of treatment (brief clinical recommendations)

Ermakova E.I.; Balan V.E.; Tikhomirova E.V.; Lazareva I.N.; Lapina A.V.; Panina E.M.

doi:https://doi.org/10.17116/rosakush201717689-95

Ermakova E.I.

FGBU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Ministerstva zdravookhraneniia Rossii, Moskva

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Tikhomirova E.V.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii"

Lazareva I.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Lapina A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Panina E.M.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Genitourinary syndrome of menopause: diagnosis and principles of treatment (brief clinical recommendations)

Authors:

Ermakova E.I., Balan V.E., Tikhomirova E.V., Lazareva I.N., Lapina A.V., Panina E.M.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2017;17(6): 89‑95

DOI: 10.17116/rosakush201717689-95

Read: 33743 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ermakova EI, Balan VE, Tikhomirova EV, Lazareva IN, Lapina AV, Panina EM. Genitourinary syndrome of menopause: diagnosis and principles of treatment (brief clinical recommendations). Russian Bulletin of Obstetrician-Gynecologist. 2017;17(6):89‑95. (In Russ.)
https://doi.org/10.17116/rosakush201717689-95

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Scleroatrophic lichen of the vulva: is it possible to solve the problem?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):47-53

Hypertensive disorders of pregnancy as a risk factor for chronic non-communicable diseases. Russian Journal of Preventive Medicine. 2025;(6):114-119

Abstract:

Objective: to provide basic clinical scientific data based on current evidence for anatomical and physiological changes in the urogenital tract of peri- and postmenopausal women and on the principles of management of patients with genitourinary syndrome of menopause. Analysis of published works by Russian and foreign authors show that these clinical recommen-dations give the current terminology of urogenital disorders in peri- and postmenopausal women and data on the etiopathogenesis, clinical presentations, diagnosis, and treatments of genitourinary syndrome of menopause — vulvovaginal atrophy and urinary disorders. Measures for prevention of this disease are proposed.

Keywords:

postmenopause

urogenital disorders

vulvovaginal atrophy

genitourinary syndrome of menopause

Authors:

Ermakova E.I.

FGBU "Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova" Ministerstva zdravookhraneniia Rossii, Moskva

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Tikhomirova E.V.

GBUZ MO "Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii"

Lazareva I.N.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Lapina A.V.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Panina E.M.

Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Moscow Region, Moscow, Russia

Close metadata

References:

Sinha A and Ewies AAA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013;16:305-312.
Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause. 2012;19:630-635.
Frank SM, Ziegler C, Kokot-Kierepa M, Maamari R, Nappi RE. Vaginal Health: Insights, Views & Attitudes (VIVA) survey — Canadian cohort. Menopause Int. 2012.
Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women’s Health Initiative. Maturitas. 2004;49:292-303.
Rosano GMC, Vitale C, Silvestri A, Fini M. Metabolic and vascular effect of progestins in postmenopause. Maturitas. 2003;46:17-29.
Hextall E. Esrogens in the funtion uretral tract. Maturitas. 2000;36:83-92.
Balan VE, Gadzhieva ZK. Violations of urination in menopause and the principles of their treatment. Russkii meditsinskii zhurnal. 2000;8:7:40-44. (In Russ.)
Manukhin IB, Tumilovich LG, Gevorkyan MA. Clinical lectures on gynecological endocrinology. 2nd edition. Moscow: GEOTAR-Media Publishing House. 2003;246-256. (In Russ.)
Pickar JH. Emerging therapies for postmenopausal vaginal atrophy. Maturitas. 2013;75:3-6.
The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:9:888-902.
Palacios S. Managing urogenital atrophy. Maturitas. 2009;63:315-318.
Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13:509-522.
Basaran M, Kosif R, Bayar U, Civelek B. Characteristics of external genitalia in pre-and postmenopausal women. Climacteric. 2008;11:416-421.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause. Menopause. 2015;22:11:1155-1174.
Adamyan LV, Kurilo LF, Glybina TM, Okulov AB. Anomalies in the development of the organs of the female reproductive system: a new view on morphogenesis. Problemy reproduktsii. 2009;4:10-19. (In Russ.)
Monz D, Pons M, Hampel C, Hunskaer S, Quail D, Samsioe G, Sykes D, Wagg A, Papanicolaou S. Patient — repoted impact of urinary incontinence. Results from treatment seeking women in 14 European countries. Maturitas. 2005;52:2:25-28.
Esefidze ZhT. Clinic, diagnosis and treatment of atrophic vaginitis in postmenopausal women. RMJ. 2001;9:370. (In Russ.)
Castelo-Branco C, Jes´us Cancelo M, Villero J, Nohales F, Juli´a MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52:46-52.
Smetnik VP. Estrogens. Prakticheskaya meditsina. 2012;128-133. (In Russ.)
Lingman K. Genuine stress incontinence. Curr Obstet Gynecol. 2001;2:353-358.
Сardozo L, Staskin D. Textbook of female urology and urogynaecology. 2005;183-227.
Kulakov VI, Apolikhina IA. Urinary incontinence in women: new opportunities in diagnosis and treatment. Gynecology. 2004;4:3:103-105. (In Russ.)
Kirlhin V, Rage T, Keegan P, Atiemo K, Cody ID, Me Clinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev.
Shah SM, Gaunay GS. Treatment options for intrinsic sphincter deficiency. Nat Rev Urol Journal List G Chir. 2013;34:7-8:189-194.
Sivkov AV, Romich VV. Pharmacotherapy of the hyperactive bladder. Consilium medicum. 2002;7:348-354. (In Russ.)
Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C. Efficacy and tolerability of mirabegron, a β³-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol. 2013;63:2:283-295.
Chapple C, Kaplan S, Mitcheson H. et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)adrenoceptor agonist, in overactive bladder (OAB). Eur Urol. 2013;62:2:296-305.
Rossanese M, Novara G, Challacombe B, Iannetti A, Dasgupta P, Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int. 2015;115:32-40.
Moore KH. Conservative management for urinary incontinence. Baillieres Best Pract Res Clin Obstet Gynecol. 2000;14:2:251-289.